$2.3M for development of new treatments for ovarian cancer

MONTREALApril 6, 2021 /CNW Telbec/ – Ovarian cancer is the 5th most common cancer among women, as well as one of the most fatal. It is estimated that 3,100 Canadian women will be diagnosed each year, and 55 per cent of them will not live beyond five years from their diagnosis.* To address these alarming statistics, IRICoR and Ovarian Cancer Canada joined forces for the launch of the pan-Canadian LeadAction Ovarian Cancer Competition.

*Source: Canadian Cancer Society, 2020

Today, IRICoR and Ovarian Cancer Canada are proud to announce the three winners of this competition, which aims to support research efforts related to the discovery of new treatments for women with ovarian cancer. A total $2.3M will be invested over the next two (2) years, namely $1.15M from IRICoR and $1.15M from Ovarian Cancer Canada’s OvCAN initiative, largely funded by Health Canada.

To read the press release, here

To read our article in Le Devoir, here  (only in French)

To read our article in insights magazine, here  (p78-79)

© 2008-2021 IRICoR